HSBC analyst Morten Herholdt raised the firm’s price target on Johnson & Johnson to $280 from $265 and keeps a Buy rating on the shares. The firm says the uncertain macro backdrop, rising geopolitical risk, and lower exposure to AI disruption risks could attract investors to healthcare and drive outperformance in the coming quarter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- District court rules federal limits to vaccines not based on science, NYT says
- 3 Best ETFs to Invest In, According to AI Analyst, 03/16/2026
- J&J announces Phase 1 study of erdafitinib met primary safety endpoint
- Monte Rosa Therapeutics announces clinical supply agreement with Johnson & Johnson
- CG Oncology price target raised to $72 from $65 at BofA